Form 4: Annovis Bio Director Bruck Claudine Reports Stock Option Grant

Director Claudine Bruck reports the acquisition of stock options in Annovis Bio, Inc.

Summary

• Claudine Bruck, a director of Annovis Bio, Inc., filed a Form 4 on July 3, 2024, reporting a transaction.
• On November 17, 2023, Bruck acquired stock options to purchase 26,200 shares of Annovis Bio common stock at an exercise price of $6.07.
• The options vest immediately and expire on November 17, 2033.
• The stock option grant was contingent upon stockholder approval of an amendment to the 2019 Equity Incentive Plan, which increased the number of shares issuable thereunder from 2,000,000 to 3,000,000 and was approved on June 12, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. The immediate vesting is a slightly positive signal.

Positives

• The immediate vesting of the options suggests confidence in the company's future performance.
• The director's acquisition of options aligns her interests with those of shareholders.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of those with the most knowledge of the company's prospects.

Stakeholder Impact

• The stock option grant aligns the director's interests with shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates